Cantor Fitzgerald raises ARS Pharmaceuticals stock price target on CSU program potential

Cantor Fitzgerald raised its price target on ARS Pharmaceuticals (NASDAQ: SPRY) to $30 from $12 while reiterating an Overweight rating, implying strong conviction in the company’s chronic spontaneous urticaria flare program. The stock is already up 18% over the past week to $9.40, with Wall Street maintaining a Strong Buy consensus and targets spanning $25 to $32. Offset by a Q1 2026 EPS miss of -$0.61 versus -$0.49 expected, the revenue print was roughly in line at $22.7 million versus $22.67 million.

Analysis

The market is starting to re-rate SPRY from a one-product commercial story into an event-driven pipeline name. That matters because the valuation gap now depends less on current earnings quality and more on the probability-weighted size of a potential expansion indication: if the flare program works, the addressable population is meaningfully broader and more episodic, which supports higher peak revenue multiples than a simple seasonal allergy franchise. In that setup, the biggest winner is not just SPRY holders but any small-cap biotech with a de-risking catalyst and visible commercial infrastructure, because investors will pay up for optionality when cash burn is offset by a credible next leg of growth.

The key second-order effect is that consensus can stay constructive even after a weak quarter if the next catalyst is binary and near-dated. That creates a classic “bad earnings, good science” mismatch: short-term holders focus on cash burn and EPS misses, while longer-duration biotech capital underwrites the clinical readout. The reversal risk is not simply trial failure; it is any delay that pushes the catalyst beyond the next 1-2 quarters, because the market will then re-anchor to dilution risk and discount the program as a story rather than an asset.

The contrarian view is that the current move may already be pricing in too much conviction for a pre-data Phase 2 asset. When sell-side price targets cluster tightly above spot, upside can become self-limiting unless the next data package is clearly differentiated versus standard care; otherwise the stock can drift as momentum buyers exit and fundamental buyers wait for validation. In practical terms, the stock is likely more sensitive to trial timing and financing optics over the next 30-90 days than to the headline target-price reset itself.

Key Decisions for Investors

• Long SPRY only as a catalyst trade, sized small, into the next clinical update window (30-90 days); use a tight stop if the stock loses recent breakout support, because downside accelerates quickly if timing slips.
• Buy SPRY call spreads on pullbacks rather than stock for the next 1-3 months; the setup favors convexity if the market starts pricing a positive Phase 2 path, while limiting damage from cash-burn/dilution concerns.
• Pair trade: long SPRY / short a profitable commercial-stage biotech with similar market cap but no near-term catalyst; the thesis is dispersion, not sector beta, and should work if investors continue rewarding binary upside over current earnings power.
• If you already own SPRY, consider monetizing part of the position into strength after the analyst-driven squeeze; the risk/reward is less attractive once price approaches the consensus target band and before actual data removes uncertainty.
• Watch for any equity financing or ATM usage in the next quarter; a financing overhang would be the cleanest catalyst for a de-rating, especially if the stock has already run ahead of clinical proof.